FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2921932947> ?p ?o ?g. }

• W2921932947 abstract "96 Background: There is an unmet need for non-invasive methods that can accurately identify patients at increased risk for clinically significant prostate cancer (PCa). SelectMDx is a urine-based molecular test that has been clinically validated for the detection of high-grade PCa. We evaluated SelectMDx clinical performance in a cohort of German men undergoing initial prostate biopsy. Methods: The study population consisted of 443 men sequentially enrolled men who underwent initial prostate biopsy between July 2009 and December 2014 due to suspected PCa. Post-DRE urine was collected from all subjects prior to biopsy, and samples stored at -70C. Urinary HOXC6 and DLX-1 mRNAs were quantified by PCR in May 2018, and RNA results combined with clinical risk factors to determine the likelihood that biopsy would identify ISUP grade group (GG) ≥ 2 (Gleason Score ≥ 7) PCa. We assessed SelectMDx performance for detection of GG ≥ 2 PCa, compared to the PCPT Risk Calculator Version 2.0 (PCPTRC, http://myprostatecancerrisk.com , accessed Oct 7, 2018). Results: For the 443 subjects enrolled, average age was 66 years (median 66, interquartile range 61 to 71), and average serum PSA level 8.8 ng/mL (6.4, 4.8 to 9.7). Cancer was detected in 243/443 (55%) men biopsied (43% GG1, 36% GG2, 9% GG3 and 12% GG4-5). The prevalence of GG2-5 PCa in this population was 31.4% (139/443). For detection of GG2 or higher PCa versus GG1 or no PCa at biopsy, SelectMDx AUC was 0.82 (95% C.I. 0.78-0.86) and the PCPTRC yielded AUC 0.75 (0.70-0.80), P < 0.001. SelectMDx sensitivity was 94% (89-98%), specificity 46% (40-52%), positive predictive value 45% (42-47%) and negative predictive value (NPV) 95% (90-97%). If the initial biopsy had been performed based on SelectMDx results alone, 46% of potentially unnecessary biopsies and 34% of all biopsies would have been avoided, while 5.8% of men with biopsy-detectable high-grade PCa (seven GG2, one GG3) may have had their diagnosis delayed. Conclusions: In this first validation study of SelectMDx in German men, the test’s clinical performance was comparable to the published EU validation study, showing a high NPV for detection of GG2 or higher PCa. These results provide further evidence for the clinical validity of SelectMDx." @default.
• W2921932947 created "2019-03-22" @default.
• W2921932947 creator A5001106178 @default.
• W2921932947 creator A5024174357 @default.
• W2921932947 creator A5027168328 @default.
• W2921932947 creator A5030545703 @default.
• W2921932947 creator A5049251419 @default.
• W2921932947 creator A5056252192 @default.
• W2921932947 creator A5089012338 @default.
• W2921932947 creator A5091084272 @default.
• W2921932947 date "2019-03-01" @default.
• W2921932947 modified "2023-10-18" @default.
• W2921932947 title "Validation of a two-gene mRNA urine test for detection of high-grade prostate cancer in German men." @default.
• W2921932947 doi "https://doi.org/10.1200/jco.2019.37.7_suppl.96" @default.
• W2921932947 hasPublicationYear "2019" @default.
• W2921932947 type Work @default.
• W2921932947 sameAs 2921932947 @default.
• W2921932947 citedByCount "0" @default.
• W2921932947 crossrefType "journal-article" @default.
• W2921932947 hasAuthorship W2921932947A5001106178 @default.
• W2921932947 hasAuthorship W2921932947A5024174357 @default.
• W2921932947 hasAuthorship W2921932947A5027168328 @default.
• W2921932947 hasAuthorship W2921932947A5030545703 @default.
• W2921932947 hasAuthorship W2921932947A5049251419 @default.
• W2921932947 hasAuthorship W2921932947A5056252192 @default.
• W2921932947 hasAuthorship W2921932947A5089012338 @default.
• W2921932947 hasAuthorship W2921932947A5091084272 @default.
• W2921932947 hasConcept C119060515 @default.
• W2921932947 hasConcept C121608353 @default.
• W2921932947 hasConcept C126322002 @default.
• W2921932947 hasConcept C126894567 @default.
• W2921932947 hasConcept C2775934546 @default.
• W2921932947 hasConcept C2776235491 @default.
• W2921932947 hasConcept C2780026642 @default.
• W2921932947 hasConcept C2780192828 @default.
• W2921932947 hasConcept C2781217009 @default.
• W2921932947 hasConcept C2908647359 @default.
• W2921932947 hasConcept C29456083 @default.
• W2921932947 hasConcept C71924100 @default.
• W2921932947 hasConcept C99454951 @default.
• W2921932947 hasConceptScore W2921932947C119060515 @default.
• W2921932947 hasConceptScore W2921932947C121608353 @default.
• W2921932947 hasConceptScore W2921932947C126322002 @default.
• W2921932947 hasConceptScore W2921932947C126894567 @default.
• W2921932947 hasConceptScore W2921932947C2775934546 @default.
• W2921932947 hasConceptScore W2921932947C2776235491 @default.
• W2921932947 hasConceptScore W2921932947C2780026642 @default.
• W2921932947 hasConceptScore W2921932947C2780192828 @default.
• W2921932947 hasConceptScore W2921932947C2781217009 @default.
• W2921932947 hasConceptScore W2921932947C2908647359 @default.
• W2921932947 hasConceptScore W2921932947C29456083 @default.
• W2921932947 hasConceptScore W2921932947C71924100 @default.
• W2921932947 hasConceptScore W2921932947C99454951 @default.
• W2921932947 hasLocation W29219329471 @default.
• W2921932947 hasOpenAccess W2921932947 @default.
• W2921932947 hasPrimaryLocation W29219329471 @default.
• W2921932947 hasRelatedWork W1971781813 @default.
• W2921932947 hasRelatedWork W1997876046 @default.
• W2921932947 hasRelatedWork W2044785539 @default.
• W2921932947 hasRelatedWork W2063081197 @default.
• W2921932947 hasRelatedWork W2085647695 @default.
• W2921932947 hasRelatedWork W2139392222 @default.
• W2921932947 hasRelatedWork W2374386609 @default.
• W2921932947 hasRelatedWork W2606758376 @default.
• W2921932947 hasRelatedWork W2886637683 @default.
• W2921932947 hasRelatedWork W4220689252 @default.
• W2921932947 isParatext "false" @default.
• W2921932947 isRetracted "false" @default.
• W2921932947 magId "2921932947" @default.
• W2921932947 workType "article" @default.